Original contributionImmunohistochemical analysis for Sox9 reveals the cartilaginous character of chondroblastoma and chondromyxoid fibroma of the bone
Section snippets
Samples
We studied 10 cases of CB and 11 cases of CMF. Three pathologists (E. K., Y. N., and Y. I.) examined hematoxylin and eosin–stained glass slides from each tumor, and 1 paraffin block from each tumor was selected for immunohistochemistry.
Immunohistochemistry
Immunohistochemistry for Sox9 and collagen type II was performed on formalin-fixed, paraffin-embedded tissue using EnVision system (Dako Co. Glostrup, Denmark) and commercially available antibodies (Sox9: H-90, rabbit polyclonal antibody, Santa Cruz
Results
Clinical data for the 10 cases of CB and 11 cases of CMF are summarized in Table 1. The age ranges of the patients with CB and with CMF were 10 to 24 years (mean, 16.8 years) and 13 to 60 years (mean, 23.3 years), respectively. The CB tumors involved the femur in 5 patients, patella and tibia in 2 each, and humerus in 1. Nine were located around the knee. The CMF tumors involved the tibia in 3 patients, both the fibula and ilium in 2, and, in 1 patient each, the femur, rib, proximal phalanx,
Discussion
The histogenesis of both CB and CMF is still unclear, despite many investigations. CB has been suspected to be a chondroid tumor based on its ultrastructural and immunohistochemical features [6], [7], [8], [9], [10], [11]. For the character of matrix in CB, one report supports a chondrogenic character based on the presence of collagen type II [9], whereas another rules out the presence of collagen type II [13]. Analysis of cartilage growth plate signaling molecules supports the chondrogenic
Acknowledgments
We thank Dr Kishimoto, Otsu Municipal Hospital, Japan (CB case 10); Dr Yoji Urata, Kyoto City Hospital, Japan (CMF case 7); Dr Kenji Notohara, Kurashiki Central Hospital, Japan (CMF case 9); Dr Nobuhito Araki, Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan (CMF case 10); and Dr Kanade Katsura, Kyoto Second Red Cross Hospital, Japan (CMF case 11).
References (34)
- et al.
Differentiation and proliferative activity in benign and malignant cartilage tumors of bone
Hum Pathol
(1995) - et al.
Ultrastructural cytochemical demonstration of proteoglycans and calcium in the extracellular matrix of chondroblastomas
Hum Pathol
(1994) - et al.
Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9
Cell
(1994) - et al.
SOX9 binds DNA, activates transcription, and coexpresses with type II collagen during chondrogenesis in the mouse
Dev Biol
(1997) - et al.
Transcriptional mechanisms of chondrocyte differentiation
Matrix Biol
(2000) - et al.
L-Sox5, Sox6 and Sox9 control essential steps of the chondrocyte differentiation pathway
Osteoarthritis Cartilage
(2001) - et al.
Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors
Hum Pathol
(2003) - et al.
Sinonasal chondromyxoid fibroma
Ann Diagn Pathol
(2009) - et al.
Benign chondroblastoma of bone; a reinterpretation of the so-called calcifying or chondromatous giant cell tumor
Am J Pathol
(1942)
Chondroblastoma
Chondromyxoid fibroma of bone: a distinctive benign tumor likely to be mistaken especially for chondrosarcoma
Arch Pathol
Chondromyxoid fibroma
Ultrastructure of cartilaginous tumors and S-100 protein in the tumors. With reference to the histogenesis of chondroblastoma, chondromyxoid fibroma and mesenchymal chondrosarcoma
Acta Pathol Jpn
S-100 protein in human cartilage lesions
J Bone Joint Surg Am
Immunohistochemical distribution of S-100 protein in tumors and tumor-like lesions of bone and cartilage
Cancer
Chondroblastoma of bone. A clinical, radiological, light and immunohistochemical study
Virchows Arch A Pathol Anat Histopathol
Cited by (42)
Expression of SATB2, RUNX2, and SOX9 and possible osteoblastic and chondroblastic differentiation in chondroblastoma
2023, Pathology Research and PracticeImmunohistochemical analysis of 36 cases of chondroblastomas: A single institutional experience
2020, Annals of Diagnostic PathologyCitation Excerpt :SOX9 is another immunomarker, positive expression of which, as observed in all chondroblastomas, reinforces their cartilaginous character, rather than bone origin, as proposed by some authors [23,24]. However, SOX9 lacks specificity in differentiating a chondroblastoma from other chondroid tumors, especially a CMF [25]. While most cases in the present study were treated with curettage and grafting or surgical excision, seven patients were treated with radiofrequency ablation and none with denosumab, which is considered in the management of certain GCTBs at our institution [6].
Bone Lesions
2020, Gnepp's Diagnostic Surgical Pathology of the Head and Neck, Third EditionUpdates in Primary Bone Tumors: Current Challenges and New Opportunities in Cytopathology
2018, Surgical Pathology Clinics